NEPHROFLOW
LOE ApproachingNDAINJECTIONINJECTABLE
Approved
Dec 1984
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 12h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
NEPHROFLOW is an injectable diagnostic or therapeutic agent approved in 1984 by GE HealthCare. The exact mechanism of action and clinical indication are not publicly specified in available data. The product is administered via injection and represents a legacy NDA with over 40 years of market presence.
LOE Approaching
With LOE approaching and competitive pressure at 30%, the brand team is likely in defensive/transition mode with reduced commercial headcount and focus shifting to managed decline or lifecycle extension strategies.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
NEPHROFLOW currently has zero linked job openings, reflecting its LOE-approaching lifecycle stage and mature market position. Career development on this product is limited; professionals should expect stability but limited growth, with roles focused on revenue protection rather than expansion.
Brand ManagerField Sales Representative
Worked on NEPHROFLOW at GE HealthCare? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.